[go: up one dir, main page]

LT2501413T - Polimero-vaisto konjugato rūgšties druskų formos - Google Patents

Polimero-vaisto konjugato rūgšties druskų formos

Info

Publication number
LT2501413T
LT2501413T LTEP10782159.7T LT10782159T LT2501413T LT 2501413 T LT2501413 T LT 2501413T LT 10782159 T LT10782159 T LT 10782159T LT 2501413 T LT2501413 T LT 2501413T
Authority
LT
Lithuania
Prior art keywords
polymer
acid salt
salt forms
drug conjugates
conjugates
Prior art date
Application number
LTEP10782159.7T
Other languages
English (en)
Inventor
Anthony CHONG
Seoju Lee
Bhalchandra JOSHI
Brian Bray
Shaoyong Nie
Patrick Spence
Antoni Kozlowski
Samuel Mcmanus
Sachin Tipnis
Greg Lavaty
David Swallow
Anthony Schaefer
John Handley
Original Assignee
Nektar Therapeutics
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nektar Therapeutics filed Critical Nektar Therapeutics
Publication of LT2501413T publication Critical patent/LT2501413T/lt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
    • C08G65/32—Polymers modified by chemical after-treatment
    • C08G65/329—Polymers modified by chemical after-treatment with organic compounds
    • C08G65/331—Polymers modified by chemical after-treatment with organic compounds containing oxygen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
    • C07C51/41—Preparation of salts of carboxylic acids
    • C07C51/412—Preparation of salts of carboxylic acids by conversion of the acids, their salts, esters or anhydrides with the same carboxylic acid part
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C53/00—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen
    • C07C53/15—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen containing halogen
    • C07C53/16—Halogenated acetic acids
    • C07C53/18—Halogenated acetic acids containing fluorine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
    • C08G65/32—Polymers modified by chemical after-treatment
    • C08G65/329—Polymers modified by chemical after-treatment with organic compounds
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
    • C08G65/32—Polymers modified by chemical after-treatment
    • C08G65/329—Polymers modified by chemical after-treatment with organic compounds
    • C08G65/333—Polymers modified by chemical after-treatment with organic compounds containing nitrogen
    • C08G65/33396—Polymers modified by chemical after-treatment with organic compounds containing nitrogen having oxygen in addition to nitrogen
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/34—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from hydroxy compounds or their metallic derivatives
    • C08G65/48—Polymers modified by chemical after-treatment
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L2203/00—Applications
    • C08L2203/02—Applications for biomedical use

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Polymers & Plastics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pulmonology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polyethers (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Cephalosporin Compounds (AREA)
  • Support Of Aerials (AREA)
LTEP10782159.7T 2009-11-18 2010-11-18 Polimero-vaisto konjugato rūgšties druskų formos LT2501413T (lt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US26246309P 2009-11-18 2009-11-18
US29007209P 2009-12-24 2009-12-24
PCT/US2010/057289 WO2011063156A2 (en) 2009-11-18 2010-11-18 Acid salt forms of polymer-drug conjugates and alkoxylation methods

Publications (1)

Publication Number Publication Date
LT2501413T true LT2501413T (lt) 2019-05-10

Family

ID=43639124

Family Applications (1)

Application Number Title Priority Date Filing Date
LTEP10782159.7T LT2501413T (lt) 2009-11-18 2010-11-18 Polimero-vaisto konjugato rūgšties druskų formos

Country Status (24)

Country Link
US (5) US9226969B2 (lt)
EP (3) EP3498754A1 (lt)
JP (3) JP5901073B2 (lt)
KR (2) KR101779229B1 (lt)
CN (2) CN102711836B (lt)
AU (1) AU2010321882B2 (lt)
BR (2) BR112012011943A2 (lt)
CA (3) CA2780779C (lt)
CY (1) CY1121700T1 (lt)
DK (1) DK2501413T3 (lt)
EA (2) EA023503B1 (lt)
ES (2) ES2723026T3 (lt)
HR (1) HRP20191138T1 (lt)
HU (1) HUE043689T2 (lt)
IL (2) IL219866A (lt)
LT (1) LT2501413T (lt)
ME (1) ME03396B (lt)
MX (2) MX338134B (lt)
PL (1) PL2501413T3 (lt)
PT (1) PT2501413T (lt)
RS (1) RS58901B1 (lt)
SI (1) SI2501413T1 (lt)
SM (1) SMT201900294T1 (lt)
WO (2) WO2011063156A2 (lt)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8852638B2 (en) 2005-09-30 2014-10-07 Durect Corporation Sustained release small molecule drug formulation
EP2907524A1 (en) 2007-05-25 2015-08-19 RB Pharmaceuticals Limited Sustained delivery formulations of risperidone compounds
LT2501413T (lt) * 2009-11-18 2019-05-10 Nektar Therapeutics Polimero-vaisto konjugato rūgšties druskų formos
US9272044B2 (en) 2010-06-08 2016-03-01 Indivior Uk Limited Injectable flowable composition buprenorphine
GB2481017B (en) 2010-06-08 2015-01-07 Rb Pharmaceuticals Ltd Microparticle buprenorphine suspension
JP6138140B2 (ja) * 2011-10-25 2017-05-31 ネクター セラピューティクス 癌患者の治療
AU2013253098A1 (en) * 2012-04-26 2014-11-13 Amylex Pharmaceuticals, Inc Novel composition for extracorporeal reduction of Beta-Amyloids and process for producing thereof
JP6300460B2 (ja) * 2012-07-20 2018-03-28 キヤノン株式会社 化合物、および前記化合物を有する光音響イメージング用造影剤
WO2014036566A1 (en) * 2012-08-31 2014-03-06 Virginia Commonwealth University Clickable polyoxetane carrier for drug delivery
CA2890082C (en) 2012-11-28 2021-07-06 Nektar Therapeutics Method for assessing and predicting efficacy of breast cancer treatment with a long-acting topoisomerase i inhibitor
US9493766B2 (en) * 2013-02-04 2016-11-15 Corning Incorporated PCR reaction cleanup buffers
WO2014168986A1 (en) 2013-04-08 2014-10-16 Brown Dennis M Therapeutic benefit of suboptimally administered chemical compounds
WO2014194289A1 (en) 2013-05-31 2014-12-04 Nektar Therapeutics Method for predicting and evaluating responsiveness to cancer treatment with dna-damaging chemotherapeutic agents
CN104225611B (zh) * 2013-06-18 2017-06-30 天津键凯科技有限公司 达沙替尼与非线性构型聚乙二醇的结合物
JP7097667B2 (ja) * 2013-09-27 2022-07-08 マサチューセッツ インスティテュート オブ テクノロジー 無担体生物活性タンパク質ナノ構造体
JP5721806B2 (ja) * 2013-10-04 2015-05-20 Ｄｅｌｔａ−Ｆｌｙ Ｐｈａｒｍａ株式会社 副作用のない抗癌剤
KR102320753B1 (ko) * 2013-10-04 2021-11-02 프로린크스 엘엘시 Sn-38 서방성 컨쥬게이트
KR102501566B1 (ko) 2014-01-14 2023-02-17 넥타르 테라퓨틱스 병용 기반 치료 방법
GB201404139D0 (en) 2014-03-10 2014-04-23 Rb Pharmaceuticals Ltd Sustained release buprenorphine solution formulations
AU2015355965B2 (en) * 2014-12-04 2019-07-04 Delta-Fly Pharma, Inc. Novel PEG derivative
WO2016124976A1 (en) * 2015-02-04 2016-08-11 United Arab Emirates University Rvg derived peptides
CN108990413A (zh) 2015-08-12 2018-12-11 麻省理工学院 纳米颗粒的细胞表面偶联
CN107019803B (zh) * 2016-01-29 2020-09-15 北京键凯科技股份有限公司 具有低成瘾作用的聚乙二醇化阿片样物质
CN107375288B (zh) 2016-05-16 2019-08-23 博瑞生物医药（苏州）股份有限公司 多臂的聚合靶向抗癌偶联物
CN107469089B (zh) * 2016-06-07 2022-01-07 北京键凯科技股份有限公司 一种peg连接子及配基药物偶联物
JP7185530B2 (ja) 2016-06-13 2022-12-07 トルク セラピューティクス， インコーポレイテッド 免疫細胞機能を促進するための方法および組成物
MX2019008276A (es) 2017-01-10 2019-09-16 Nektar Therapeutics Conjugados de polimero multibrazo de compuestos agonistas de tlr y metodos de tratamiento inmunoterapeutico relacionados.
JP6853277B2 (ja) * 2017-02-02 2021-03-31 アルプスアルパイン株式会社 磁気平衡式電流センサおよびその製造方法
CN108727584B (zh) * 2017-04-21 2021-01-05 博瑞生物医药（苏州）股份有限公司 抗癌偶联物
US11191843B2 (en) 2017-04-21 2021-12-07 Brightgene Bio-Medical Technology Co., Ltd. Multi-arm targeting anti-cancer conjugate
US20200178967A1 (en) * 2017-09-01 2020-06-11 Arizona Board Of Regents On Behalf Of Arizona State University Thixotropic biocompatible gel for live cell observation in cell computed tomography
US11524033B2 (en) 2017-09-05 2022-12-13 Torque Therapeutics, Inc. Therapeutic protein compositions and methods of making and using the same
CN107854693B (zh) * 2017-11-14 2020-07-14 高瑞耀业(北京)科技有限公司 整合素受体靶向的抗癌偶联物
WO2019096096A1 (zh) * 2017-11-14 2019-05-23 博瑞生物医药（苏州）股份有限公司 多臂靶向偶联物
CN109776787B (zh) * 2017-11-14 2021-08-03 博瑞生物医药（苏州）股份有限公司 多臂靶向偶联物
JP6830165B2 (ja) 2017-12-27 2021-02-17 三洋化成工業株式会社 医薬品原薬用原料又は医薬品用添加物及びこれらを用いた医薬品原薬又は医薬品
CA3087628A1 (en) * 2018-01-12 2019-07-18 Prolynx Llc Synergistic cancer treatment
CN112367985A (zh) * 2018-01-31 2021-02-12 明尼苏达大学董事会 用于治疗肺水肿或肺炎的组合物和方法
CN110256533B (zh) * 2018-03-12 2022-05-10 博瑞生物医药（苏州）股份有限公司 一种高纯度的多臂抗癌偶联物的提取方法
CN110577552A (zh) * 2018-06-08 2019-12-17 遵义医学院 喜树碱-甘氨酸-5,6-双脱氢去甲斑蝥素结合物及其应用
KR20210072002A (ko) 2018-09-17 2021-06-16 더 칠드런스 호스피탈 오브 필라델피아 폴리머 기반 거대분자 프로드러그
CN111603567B (zh) 2019-02-22 2024-12-27 赣江新区博瑞创新医药有限公司 Cd44靶向多臂偶联物
CN114705801B (zh) * 2022-01-24 2024-02-27 中国食品药品检定研究院(国家药品监督管理局医疗器械标准管理中心、中国药品检验总所) 一种利福霉素类药物中亚硝酸根离子的测定方法

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1222261B (de) * 1963-04-20 1966-08-04 Bayer Ag Verfahren zur Herstellung von Polyaethern durch Polymerisation von Alkylenoxyden
GB1157753A (en) * 1966-06-24 1969-07-09 Bp Chem Int Ltd Improvements in or relating to Synthetic Lubricants
JPS6019790A (ja) * 1983-07-14 1985-01-31 Yakult Honsha Co Ltd 新規なカンプトテシン誘導体
US5399728A (en) * 1993-04-05 1995-03-21 Arco Chemical Technology, L.P. Process for the preparation of highly esterified alkoxylated polyol compositions
GB9704126D0 (en) * 1997-02-27 1997-04-16 Ici Plc Surfactants
DE19817676A1 (de) * 1998-04-21 1999-10-28 Bayer Ag Verfahren zur aufarbeitungsfreien Herstellung langkettiger Polyetherpolyole
WO2000066125A1 (en) 1999-04-29 2000-11-09 Aventis Pharma S.A. Method for treating cancer using camptothecin derivatives and 5-fluorouracil
DE19937114C2 (de) * 1999-08-06 2003-06-18 Bayer Ag Verfahren zur Herstellung von Polyetherpolyolen
US6762325B2 (en) 2001-05-16 2004-07-13 Nippon Shokubai Co., Ltd. Method for production of alkoxylated compound
SE523934C2 (sv) * 2001-09-24 2004-06-01 Perstorp Specialty Chem Ab Förfarande för av alkoxylering av di-, tri och polyalkoholer
US6608076B1 (en) * 2002-05-16 2003-08-19 Enzon, Inc. Camptothecin derivatives and polymeric conjugates thereof
RU2005114007A (ru) * 2002-10-09 2005-10-10 Инсерт Терапьютикс, Инк. (Us) Материалы на основе циклодекстринов, их композиции и применение
US20050043215A1 (en) 2003-02-19 2005-02-24 Tamara Minko Complex drug delivery composition and method for treating cancer
ES2725808T3 (es) * 2003-05-23 2019-09-27 Nektar Therapeutics Derivados de PEG que contienen dos cadenas de PEG
CN102172405B (zh) * 2003-09-17 2014-11-12 耐科塔医药公司 多支链聚合物的药物前体
US8394365B2 (en) 2003-09-17 2013-03-12 Nektar Therapeutics Multi-arm polymer prodrugs
CA2558583C (en) * 2004-03-15 2013-07-09 Nektar Therapeutics Al, Corporation Polymer-based compositions and conjugates of hiv entry inhibitors
JP4829120B2 (ja) * 2004-10-01 2011-12-07 株式会社ヤクルト本社 イリノテカン酸付加塩
EP1885403B1 (en) 2005-04-12 2013-05-08 Nektar Therapeutics Poly(ethyleneglycol) conjugates of Lysostaphin
EP1926768B1 (en) * 2005-07-18 2011-09-14 Nektar Therapeutics Branched functionalized polymers using branched polyol cores
US7462627B2 (en) * 2006-02-09 2008-12-09 Enzon Pharmaceuticals, Inc. Multi-arm polymeric conjugates of 7-ethyl-10-hydroxycamptothecin for treatment of breast, colorectal, pancreatic, ovarian and lung cancers
IE20060565A1 (en) * 2006-07-28 2008-02-06 Eurand Pharmaceuticals Ltd Drug delivery system based on regioselectively amidated hyaluronic acid
JP5105166B2 (ja) * 2007-12-19 2012-12-19 公益財団法人野口研究所 ポリエーテルの製造方法
LT2501413T (lt) 2009-11-18 2019-05-10 Nektar Therapeutics Polimero-vaisto konjugato rūgšties druskų formos

Also Published As

Publication number Publication date
JP2016006127A (ja) 2016-01-14
US9226969B2 (en) 2016-01-05
BR112012011947B1 (pt) 2021-05-18
EP2501412A1 (en) 2012-09-26
EP2501413A2 (en) 2012-09-26
EA201200751A8 (ru) 2014-07-30
RS58901B1 (sr) 2019-08-30
JP2013511539A (ja) 2013-04-04
CA2780645A1 (en) 2011-05-26
PT2501413T (pt) 2019-07-10
MX338134B (es) 2016-04-01
US20130143909A1 (en) 2013-06-06
WO2011063158A1 (en) 2011-05-26
WO2011063156A3 (en) 2011-08-25
CN102711836B (zh) 2017-05-10
CN102711836A (zh) 2012-10-03
ES2623677T3 (es) 2017-07-12
HUE043689T2 (hu) 2019-09-30
EP2501413B1 (en) 2019-03-27
KR20120104243A (ko) 2012-09-20
CA2780645C (en) 2018-01-16
MX337393B (es) 2016-03-02
CA2780779C (en) 2020-02-04
KR20120101070A (ko) 2012-09-12
MX2012005795A (es) 2012-09-07
EA201290342A1 (ru) 2012-10-30
US20150105519A1 (en) 2015-04-16
EA201290342A8 (ru) 2014-07-30
US9320808B2 (en) 2016-04-26
IL219866A (en) 2017-03-30
CA3063465C (en) 2023-01-03
JP5951496B2 (ja) 2016-07-13
CA3063465A1 (en) 2011-05-26
CN102711837B (zh) 2016-10-19
US20210024693A1 (en) 2021-01-28
CN102711837A (zh) 2012-10-03
EA201200751A1 (ru) 2013-03-29
EA024533B1 (ru) 2016-09-30
SMT201900294T1 (it) 2019-07-11
PL2501413T3 (pl) 2019-09-30
JP5901073B2 (ja) 2016-04-06
IL219865A0 (en) 2012-07-31
US11834553B2 (en) 2023-12-05
CY1121700T1 (el) 2020-07-31
AU2010321882A1 (en) 2012-05-31
HRP20191138T1 (hr) 2019-09-20
KR101790804B1 (ko) 2017-10-26
IL219865A (en) 2017-03-30
EP2501412B1 (en) 2017-03-29
ME03396B (me) 2020-01-20
US20160200867A1 (en) 2016-07-14
BR112012011943A2 (pt) 2018-09-11
US20130231359A1 (en) 2013-09-05
BR112012011947B8 (pt) 2021-05-25
CA2780779A1 (en) 2011-05-26
BR112012011947A2 (pt) 2018-09-11
SI2501413T1 (sl) 2019-06-28
JP2013511540A (ja) 2013-04-04
EP3498754A1 (en) 2019-06-19
DK2501413T3 (da) 2019-06-11
AU2010321880A1 (en) 2012-06-07
WO2011063156A2 (en) 2011-05-26
KR101779229B1 (ko) 2017-09-18
ES2723026T3 (es) 2019-08-21
AU2010321882B2 (en) 2016-01-14
EA023503B1 (ru) 2016-06-30
IL219866A0 (en) 2012-07-31
MX2012005794A (es) 2012-10-09

Similar Documents

Publication Publication Date Title
HUE043689T2 (hu) Polimer-gyógyszer savas sói
ZA201203615B (en) Derivatives of 1-amino-2-cyclobutylethylboronic acid
EP2389375A4 (en) HYDROXAMIC ACID DERIVATIVES
ZA201308086B (en) Derivatives of 1-anino-2-cyclopropylboronic acid
ZA201105093B (en) N-acyl anthranilic acid derivative or salt thereof
ME02117B (me) 2-aminobenzimidazol-5-karboksamidi kao anti-inflamatorni agensi
ZA201108850B (en) Solid compositions comprising 5-aminolevulinic acid
HK1169648A1 (en) Novel acetylsalicylic acid salts
IL217001A0 (en) Preparation of substituted 2-fluoroacrylic acid derivatives
ZA201109138B (en) Pharmaceutical composition having improved solubility
GB0906379D0 (en) Reduced sodium salt
GB0904658D0 (en) Novel microbiocides
ZA201104757B (en) Novel microbiocides
IL206524A0 (en) 4-dimethylminobutyric acid derivatives
ZA201202859B (en) Polymorphs of sorafeinib acid addition salts
PL2470171T3 (pl) Przeciwdrobnoustrojowe pochodne kwasu aminosalicylowego
EP2459540A4 (en) PREPARATION OF FIPAMEZOLE
GB0906872D0 (en) Amino acid derivatives
GB2493855B8 (en) Reduced sodium salt
GB201009520D0 (en) Amino acid derivatives
GB201014094D0 (en) Amino acid derivatives
GB201216287D0 (en) Reduced sodium salt
GB0900991D0 (en) Novel microbiocides
GB0903108D0 (en) Novel microbiocides
GB0901420D0 (en) Formula 1-2050